Table 2.
Descriptive characteristics of all patients with prior liver transplantation and subsequent immunotherapy
|
|
All
|
Rejection
|
No rejection
|
P
value
|
| Total (%) | 28 | 9 (32) | 19(68) | |
| Gender (M/F; %M) | 22/6 (79) | 6/3 (67) | 16/3 (84) | 0.29 |
| Age | 61 (53-66) | 63 (34-67.5) | 59 (54-64) | 1.00 |
| Year after transplant | 3.9 (2.5-6.5) | 2.9 (1.2-3.1) | 5.3 (2.7-8.0) | 0.02 |
| Indication (%) | 0.93 | |||
| HCC | 19 (68) | 6 (67) | 13 (68) | |
| Melanoma | 8 (29) | 3 (33) | 5 (26) | |
| SCC of lung | 1 (4) | 0 (0) | 1 (5) | |
| Line of systemic therapy | 2 (1-3) | 2 (1-3) | 2 (1-4) | 0.52 |
| Immunotherapy by drug (%) | 0.92 | |||
| Nivolumab | 15 (54) | 5 (56) | 10 (53) | |
| Pembrolizumab | 10 (36) | 3 (33) | 7 (37) | |
| Ipilimumab | 4 (14) | 1 (11) | 3 (16) | |
| Immunotherapy by class (%) | 1.00 | |||
| PD1/PD-L1 | 24 (86) | 8 (89) | 16 (84) | |
| CTLA-4 | 3 (11) | 1 (11) | 2 (11) | |
| Both | 1 (4) | 0 (0) | 1 (5) | |
| PD-L1 positivity (%) | ||||
| Graft | 5/7 (71) | 4/4 (100) | 1/3 (33) | 0.053 |
| Tumor | 4/8 (50) | 2/3 (67) | 2/5 (40) | 0.47 |
| Immunosuppression (%) | ||||
| Single agent tacrolimus | 10 (36) | 2 (22) | 8 (42) | 0.31 |
| Single agent mTOR-inhibitor | 6 (21) | 3 (33) | 3 (16) | 0.29 |
| Tacrolimus with mTOR-inhibitor | 5 (18) | 1 (11) | 4 (21) | 0.52 |
| Others | 7 (25) | 3 (33) | 4 (21) | 0.48 |
| Acute rejection (%) | 9 (32) | |||
| Mortality in 30 d (%) | 6 (21) | 5 (56) | 1 (5) | 0.002 |
| Progression-free survival | 3 ± 0.6 | 1.0 ± 0.1 | 3.5 ± 1.1 | 0.02 |
| Overall survival | 10.6 ± 5.3 | 1.0 ± 0.1 | 19.2 ± 5.5 | 0.001 |
CTLA-4: Cytotoxic T-Lymphocyte antigen-4; F: Female; HCC: Hepatocellular carcinoma; M: Male; mTOR: Mammalian target of rapamycin; PD-1: Programmed cell death protein-1; PD-L1: Programmed death ligand-1; SCC: Squamous-cell carcinoma.